.png)
SummaryFor a market-access or pricing lead in DACH, the tool question is not which global suite is broadest, but which one actually carries the German detail a decision needs: the AMNOG benefit assessment, the AVWG transparency list, and a usable reimbursement-price history, ideally in English for an HQ team. This guide compares the categories of market-access and reimbursement pricing tools by exactly those criteria. It is written for professionals, not patients.
Four things separate a DACH-capable tool from a broad global one. First, AMNOG depth: the early benefit assessment and its outcome categories, not just a headline. Second, the AVWG transparency list and reference prices. Third, a reimbursement-price history you can query, not a single current value. Fourth, English access, because the decisions are often reviewed by a headquarters team outside Germany. A tool can be excellent globally and still miss all four.
The table compares tool categories on the German depth that decides a DACH market-access question.
| Tool | AMNOG / benefit-assessment depth | AVWG transparency list | Reimbursement price history | HTA coverage (G-BA/IQWiG) | English access | Integration |
|---|---|---|---|---|---|---|
| pharmazie.com | integrated AMNOG + reimbursement amounts | yes | yes, via Pharmonitor | linked | yes | REST API |
| Global HTA / pricing suite (e.g. IQVIA, GlobalData) | summary level | limited | yes, varies | broad, many countries | yes | yes |
| AMNOG-focused monitor (e.g. AMNOG-Monitor, Pharm-Analytics, IGES) | deep on AMNOG | partial | partial | AMNOG-focused | limited | varies |
| Classic pharmacy-tax system | limited | partial | limited | no | no | limited |
After a new medicine launches, the G-BA conducts an early benefit assessment under section 35a SGB V, and a reimbursement amount is then negotiated under section 130b SGB V. A capable tool records the assessment outcome and the negotiated amount together, so a pricing team sees both the clinical verdict and the price it produced. A summary that carries only the outcome, without the amount and its history, cannot support a pricing model.
The AVWG transparency list links products to reference prices (Festbeträge) and reimbursement information, which is where substitution and pricing pressure actually bite. For a pricing team it is not a legal footnote but a working dataset: it shows where a product sits against its reference-price group and where a competitor move would change the position. A tool that integrates it saves the team from reconstructing it from separate sources.
A single reimbursement amount is a snapshot; the series is the decision tool. A reimbursement-price history shows how a group moved through AMNOG negotiations, reference-price adjustments and moratorium periods, which is what a defensible pricing position needs. pharmazie.com provides this history through Pharmonitor, alongside competitor prices and reference prices, so the trend and the current value sit together. Our comparison of price monitoring tools for DACH goes deeper on the pricing side.
The honest answer is often both. A global suite such as IQVIA or GlobalData is built for cross-country reference pricing across many markets. A DACH-specialised tool carries the German AMNOG, AVWG and reimbursement-history depth those suites summarise. Teams handling German launches usually run a DACH-deep tool for the market where the decision is made, and a global suite for breadth, rather than forcing one to do both.
The right fit follows the team. A German market-access team may work directly in the AMNOG and AVWG data. A global HQ team needs the same German depth in English, so the pricing case can be reviewed centrally without a German-only interface. Consultancies working project by project value flexible export and, again, English access. The underlying German pricing detail is described on our pharma pricing and market access page.
For DACH market access, the strongest tool is the one with real German depth: AMNOG and benefit-assessment detail, the AVWG transparency list, a reimbursement-price history and English access. pharmazie.com provides that depth through its AMNOG module, transparency list and Pharmonitor, within the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. The clearest way to judge the fit for your team is a short demo.
Further reading: Price monitoring tools for DACH · Pharma pricing and market access
